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Obesity is a major health problem and an immense economic burden on the health care systems both in the United States and the
rest of the world. The prevalence of obesity in children and adults in the United States has increased dramatically over the past
decade.Besidesenvironmentalfactors,geneticfactorsareknowntoplayanimportantroleinthepathogenesisofobesity.Genome-
wide association studies (GWAS) have revealed strongly associated genomic variants associated with most common disorders;
indeed there is general consensus on these ﬁndings from generally positive replication outcomes by independent groups. To date,
there have been only a few GWAS-related reports for childhood obesity speciﬁcally, with studies primarily uncovering loci in the
adult setting instead. It is clear that a number of loci previously reported from GWAS analyses of adult BMI and/or obesity also
play a role in childhood obesity.
1. Deﬁnition andEpidemiology of
Childhood Obesity
Obesityisamajorhealthprobleminmodernsocieties,witha
prevalence of up to 25% in Western societies and an increas-
ing incidence in children [1]. Obesity, plus the associated
insulin resistance [2, 3], is also considered a contributor to
the major causes of death in the United States and is an
important risk factor for type 2 diabetes (T2D), cardiovascu-
lardiseases(CVD),hypertension,andotherchronicdiseases.
Approximately 70% of obese adolescents grow up to
become obese adults [4–6]. The main direct adverse eﬀects
ofchildhoodobesityincludeorthopediccomplications,sleep
apnea, and psychosocial disorders [7, 8]. Obesity present in
adolescence has been shown to be associated with increased
overall mortality in adults [9]; overweight children followed
up for 40 [10]a n d5 5y e a r s[ 11]w e r em o r el i k e l yt oh a v e
CVD and digestive diseases, and to die from any cause as
compared with those who were lean.
Obesity is a complex disease that involves interactions
betweenenvironmentalandgeneticfactors.Excessinadipose
tissue mass can be seen as a disruption in the balance
between energy intake and expenditure. In modern times,
this excess in adipose tissue fuel storage is considered a
disease; however, a better viewpoint would be that obesity
is a survival advantage that has gone astray that is, what is
now considered a disease was probably advantageous when
food was less available and a high level of energy expenditure
through physical activity was a way of life [12].
The true prevalence of childhood obesity is diﬃcult to
empirically quantify as there is currently no internationally
accepted deﬁnition; however, in general terms, childhood
obesity is considered to have reached epidemic levels in
developed countries.
Approximately 25% of children in the US are overweight
and approximately 11% are obese. In the 10-year period
between the National Health and Nutrition Examination
Survey (NHANES) II (1976–1980) and NHANES III (1988–
1991), the prevalence of overweight children in the USA had
increased by approximately forty percent [1]. Examination
of historical standards for deﬁning overweight in children
from many countries tells us that the distribution of BMI
is becoming increasingly skewed [13]. The lower part of the
distribution has shifted relatively little whereas the upper2 Journal of Obesity
part has widened substantially. This ﬁnding suggests that
many children may be more susceptible (genetically or
socially) to inﬂuence by the changing environment.
Although the deﬁnition of obesity and overweight has
changed over time [14, 15], it can be deﬁned as an excess
of body fat. The deﬁnition of childhood obesity continues to
be problematic due to the fact that almost all deﬁnitions use
some variant of BMI (body mass index). A range of other
methods are available which allow for accurate estimates of
total body fat; however, none of these are widely available
and/or are easily applicable to the clinical situation. Body
weight is reasonably well correlated with body fat but is
also highly correlated with height, and children of the
same weight but diﬀerent heights can have widely diﬀering
amounts of adiposity, but in adults BMI correlates more
strongly with more speciﬁc measurements of body fat, that
is, BMI is useful for depicting overweight in the population
but is an imperfect approximation of excess adiposity [16].
In addition, the relation between BMI and body fat in
children varies widely with age and with pubertal matura-
tion. This in itself makes BMI deﬁnitions of overweight for
childrenmore complex thandeﬁnitions for adults,whichuse
a single cutoﬀ value for all ages. Deﬁnitions of overweight
that use BMI-for-age can be based on a number of diﬀerent
standards that all give slightly diﬀerent results, and all are
essentially statistical not functional deﬁnitions. However,
useful percentile charts relating BMI to age have now been
published in several countries [17]. The Center for Disease
ControlandPreventiondeﬁnedoverweightasatorabovethe
95th percentile of BMI for age and “at risk for overweight”
as between 85th to 95th percentile of BMI for age [18, 19].
European researchers classiﬁed overweight as at or above
85th percentile and obesity as at or above 95th percentile
of BMI [20]. A recent report from the Institute of Medicine
has speciﬁcally used the term “obesity” to characterize BMI
≥ 95th percentile in children and adolescents [21]. By
late adolescence, these percentiles approach those used for
adult deﬁnitions; the 95th percentile is then approximately
30kg/m2 [8]. These statistical percentile deﬁnitions are now
general guidelines for clinicians and others [19].
2. Therapeutic Options
Data supporting the use of pharmacological therapy for
pediatric overweight are limited and inconclusive [22].
Sibutraminehasbeenstudiedinarandomizedcontrolled
trialofsevereobesity[23].Ithasbeenshowntobeeﬃcacious
as compared with behavior therapy alone, but it may be
associated with side eﬀects including increases in heart rate
and blood pressure [24]; recent clinical trial studies have
concluded that subjects with preexisting cardiovascular con-
ditions who were receiving long-term sibutramine treatment
had an increased risk of nonfatal myocardial infarction and
nonfatal stroke [25]; indeed, it was recently dropped from
further development based on the results from such clinical
trials.
Orlistat is approved for use in adolescence but its eﬃcacy
has not yet been tested extensively in young patients. Orlistat
is associated with gastrointestinal side eﬀects and requires
fat-soluble vitamin supplementation and monitoring [26,
27].
Metformin, used to treat T2D, has been used in insulin-
resistant children and adolescents who are overweight, but
long-term eﬃcacy and safety are unknown [28]. Addition-
ally, surgical approaches to treat severe adolescent obesity are
being undertaken by several centers [29].
For rare genetic and metabolic disorders, pharmacolog-
ical treatment may be useful. For example, recombinant
leptin is useful in hereditary leptin deﬁciency. Octreotide
may be useful in hypothalamic obesity [30].
3. Evidencefor aGeneticComponent inObesity
The rising prevalence of obesity can be partly explained by
environmental changes over the last 30 years, in particular
the unlimited supply of convenient, highly caloriﬁc foods
together with a sedentary lifestyle. Despite these changes,
there is also strong evidence for a genetic component to the
risk of obesity [31, 32]; indeed, obesity is now considered a
classic example of a complex multifactorial disease resulting
from the interplay between behavioral, environmental and
genetic factors which may inﬂuence individual responses to
diet and physical activity.
Ageneticcomponentforobesityisreﬂectedinprevalence
diﬀerences between racial groups, from 5% or less in Cau-
casian and Asian populations to 50% or more among Pima
Indians and South Sea Island populations [33]. In addition,
the familial occurrencesof obesity have been long noted with
theconcordanceforfatmassamongMZtwinsreportedtobe
70–90%, higher than the 35–45% concordance in DZ twins;
as such, the estimated heritability of BMI ranges from 30 to
70% [34–36].
4.PreviousGeneticStudiesinObesityand
the Need for GWASApproaches
Genome-wide linkage scans in families with the common
form of childhood obesity have yielded several loci, but the
genes in these loci have yet to be elucidated. A number
of families with rare pleiotropic obesity syndromes have
been studied by linkage analysis where chromosomal loci
for Prader-Willi syndrome [37], Alstr¨ om’s syndrome [38],
and Bardet-Biedl syndrome [39–41]h a v eb e e nm a p p e d
but the underlying molecular mechanisms have yet to be
determined.
Recent studies of genetic syndromes of obesity in rodents
have provided insights in to the underlying mechanisms that
may play a role in energy homoeostasis. In recent years,
research has begun to identify human disorders of energy
balance that arise from defects in these or related genes
[42]. These mutations have been shown to result in morbid
obesity in children without the developmental features that
commonly accompany recognized syndromes of childhood
obesity.
The severely obese ob/ob mouse strain [43] inherits its
early-onsetobesityautosomalrecessivelyandweighsapprox-
imately three-times more than normal mice by maturity.
Zhang et al. [44] cloned and characterized the ob geneJournal of Obesity 3
which is expressed primarily in white adipose tissue as the
secreted protein, leptin, a mutation of which renders these
mice leptin deﬁcient. Administration of recombinant leptin
is known to reverse the phenotypic abnormalities in these
mice entirely [45–47] while there is no eﬀect in another
strain of severely obese mice, db/db, who instead have been
characterized to have a mutation in the leptin receptor gene,
which is primarily expressed in a diﬀerent site, namely,
the hypothalamus [48]. In human studies, serum leptin
concentrations are widely recognized as being positively
correlated with obesity-related traits [49].
The behavioral and neuroendocrine eﬀects of leptin
couldpotentiallybemediatedthroughitsactionsathypotha-
lamic leptin receptors. Proopiomelanocortin (POMC) is
produced by the hypothalamus, which is subsequently
cleaved by prohormone convertases to yield peptides
(including α melanocyte stimulating hormone, αMSH) that
play a role in feeding behavior. Forty percent of POMC
neurons express mRNA for the long form of the leptin
receptor, and POMC expression is positively regulated by
leptin [50]. Work in rodents has demonstrated that αMSH
acts as a suppressor of feeding behavior; recently, mutations
in POMC associated with severe and early-onset obesity have
been described in two unrelated German subjects [51]. A
single patient with severe early-onset obesity was reported to
have compound heterozygote mutations in the prohormone
convertase 1 (PC1) gene, a key component in the proteolytic
processing of POMC [52, 53].
One form of melanocortin receptor (MC4R) is highly
expressed in areas of the hypothalamus involved in feeding;
mice with disruption of the MC4R gene are severely obese
[54]. More recently in humans, mutations in the MC4R gene
have been associated with obesity [55–58]. The MC4R gene
is the ﬁrst locus at which mutations are associated with
dominantly inherited morbid human obesity thus making
it the commonest genetic cause of human obesity described
before the era of GWAS.
5. Genome WideAssociationStudies
Overall, linkage analysis studies conducted to date have
achieved only limited success in identifying genetic deter-
minants of obesity due to various reasons, importantly
including the generic problem that the linkage analysis
approach is generally poor in identifying common genetic
variants that have modest eﬀects [59, 60]. Comparably, a
generic problem with the candidate gene association studies
is their general reliance on a suspected disease-causing
gene(s) whose identity derives from a particular biological
hypothesis on the pathogenesis of obesity. Thus, since
the pathophysiological mechanisms underlying obesity are
generally unknown, continued use of the hypothesis-driven
candidate gene association approach is likely to identify only
a relatively small fraction of the genetic risk factors for the
disease.
The GWAS approach serves the critical need for a more
comprehensive and unbiased strategy to identify causal
genes related to obesity. It is also well established that
in noncoding regions of the genome there are important
regulatory elements, such as enhancers and silencers, and
genetic variants that disrupt those elements could equally
confer susceptibility to complex disease.
The human genome and International HapMap projects
have enabled the development of unprecedented technol-
ogy and tools to investigate the genetic basis of complex
disease. The HapMap project, a large-scale eﬀort aimed at
understanding human sequence variation, has yielded new
insights into human genetic diversity that is essential for
the rigorous study design needed to maximize the likelihood
that a genetic association study will be successful [59–61].
Genome-wide genotyping of over 500,000 SNPs can now be
readily achieved in an eﬃcient and highly accurate manner
[62, 63]. Since much of human diversity is due to single
base pair variations together with variations in copy number
[64]throughoutthegenome,currentadvancesinsingle-base
extension(SBE)biochemistryandhybridization/detectionto
synthetic oligonucleotides now make it possible to accurately
genotype and quantitate allelic copy number [63, 65].
There is now a revolution occurring in SNP genotyp-
ing technology, with high-throughput genotyping methods
allowing large volumes of SNPs (105-106)t ob eg e n o t y p e d
in large cohorts of patients and controls, therefore enabling
large-scale GWAS in complex diseases. Already with this
technologycompellingevidenceforgeneticvariantsinvolved
in type 1 diabetes [66–68], type 2 diabetes [68–72], age-
related macular degeneration [73], inﬂammatory bowel
disease [74,75],heartdisease [76, 77],and breastcancer[78]
has been described.
6. Findingsfrom FirstGWAS
Analysesof Obesity
Inthepastfouryears,manygeneticlocihavebeenimplicated
for BMI from the outcomes of GWAS, primarily in adults.
Insulin-induced gene 2 (INSIG2) was the ﬁrst locus to
be reported by this method to have a role in obesity [79]b u t
replicationattemptshaveyieldedinconsistentoutcomes[80–
84]. A common genetic variant with modest relative risk (RR
= ∼1.2),rs7566605,neartheINSIG2genehasbeendescribed
to be associated with both adult and childhood obesity
from a GWAS employing 100,000 SNPs [79]. This variant,
present in 10% of individuals, was subsequently replicated
in four separate cohorts in the same study, including
individuals who were Caucasian, African American, and
children; however, three subsequent technical comments to
Science [80–82] disagreed with this observation.
The identiﬁcation of the second locus, the fat mass- and
obesity-associated gene (FTO)[ 85], which has been more
robustly observed by others [86–89], including by us [90].
Interestingly, its role in obesity pathogenesis was actually
madeindirectlyasaconsequenceofaGWASofT2D[68,71],
but it became quite clear that its primary inﬂuence is on BMI
determination which then in turn impairs glycemic control
[85]. However, the mechanism by which the variant in FTO
inﬂuences the risk of obesity is largely unknown.
Studies from both FTO knockout and FTO overexpres-
sion mouse model support the fact that FTO is directly
involved in the regulation of energy intake and metabolism4 Journal of Obesity
in mice, where the lack of FTO expression leads to lean-
ness while enhanced expression of FTO leads to obesity
[91, 92].
A French sequencing eﬀort in Caucasians (primarily
adults) has reported a set of exonic mutations in FTO;
however, due to the lack of signiﬁcant diﬀerence in the
frequencies of these variants between lean and obese indi-
viduals, this study was largely negative [93].
7.Meta-Analyses
Subsequent larger studies have uncovered eleven additional
genes [94–96], again primarily in adults, ﬁrstly melanocortin
4r e c e p t o r( MC4R) from a multicenter meta-analysis [94],
then the GIANT consortium revealed six more genes
(transmembrane protein 18 (TMEM18), potassium channel
tetramerisation domain containing 15 (KCTD15), glucosa-
mine-6-phosphate deaminase 2 (GNPDA2), SH2B adaptor
protein 1 (SH2B1), mitochondrial carrier 2 (MTCH2), and
neuronal growth regulator 1 (NEGR1)) [96], ﬁve of which
were conﬁrmed in the GWAS reported from Iceland (but
not GNPDA2 due to an unavailable proxy SNP), who also
uncovered and reported loci on 1q25, 3q27 and 12q13 [95]
and veriﬁed association with the brain-derived neurotrophic
factor (BDNF)g e n e[ 97].
The latest GIANT meta-analysis revealed multiple new
loci associated with body mass index in a study involving
a total of 249,796 individuals [98]. A total of 32 loci
reached genome wide signiﬁcance, which included ten
known loci associated with BMI, four known loci associ-
ated with weight and/or waist-hip ratio, namely, SEC16B,
TFAP2B, FAIM2, NRXN3, and eighteen new BMI loci,
namely, RBJ-ADCY3-POMC, GPRC5B-IQCK, MAP2K5-
LBXCOR1, QPCTL-GIPR, TNNI3K, SLC39A8, FLJ35779-
HMGCR, LRRN6C, TMEM160-ZC3H4, FANCL, CADM2,
PRKD1, LRP1B, PTBP2, MTIF3-GTF3A, ZNF608, RPL27A-
TUB,a n dNUDT3-HMGA1. Besides association to SNPs, a
correlated copy number variation (CNV), that is, a 21kb
deletion, was identiﬁed 50kb upstream of GPRC5B. This
study also leveraged a pediatric cohort to lend further
support for their ﬁndings.
8. Testing Adult-DiscoveredLoci inChildren
As described above, a number of genetic determinants of
adult BMI have already been established through GWAS.
One obvious question is how do these loci operate in
childhood with respect to the pathogenesis of obesity? We
have an ongoing GWAS of BMI variation in children so we
are in position to query these SNPs in our dataset of in
excess of 6,000 children with measures of BMI [99]. To date
nine such loci have yielded evidence of association to BMI
in childhood, of which variants at the FTO locus yielded
the strongest association. With a similar magnitude of
association to FTO was TMEM18 followed by GNPDA2.T h e
remaining loci with evidence for association were INSIG2,
MC4R, NEGR1, 1q25, BDNF,a n dKCTD15 (Table 1). This
is very much in line with the observations made with the
pediatric cohort utilized by Willer et al. [96].
The positive results for FTO and MC4R come as no
surprise as we previously reported their association with the
CDC-deﬁned 95th percentile of BMI, that is, obesity, in our
pediatric cohort, but limited to ages 2–18 years old [90, 106].
One of the more notable results is the positive association
with INSIG2. This association with pediatric BMI, albeit at
just the nominal level, contributes to the ongoing debate on
the relative contribution of INSIG2 in BMI determination.
However, these nine loci only explain 1.12% of the total
variation for BMI. In addition, testing pair-wise interactions
between the ﬁfteen signiﬁcant SNPs, none of the interac-
tion eﬀects were signiﬁcant suggesting that these loci act
additively on pediatric BMI [99]. As such, we do observe
a cumulative eﬀect but not as striking as reported by the
GIANT consortium in their adult cohorts [96].
A number of studies have found that body mass index
(BMI) in early life inﬂuences the risk of developing type 2
diabetes (T2D) later in life. Indeed, the same variant in IDE-
HHEX that increases the risk of developing the disease later
in life turns out to be also associated with increased BMI in
childhood [100].
9.LociSpeciﬁcallyIdentiﬁed inChildhood
ObesityGWASAnalyses
Two new loci for body-weight regulation were identiﬁed in a
joint analysis of GWAS data for early-onset extreme obesity,
that is, BMI ≥ 99th, in French and German study groups
[101], namely, SDCCAG8 and TNKS/MSRA (Table 1). In
the discovery step, association was examined in a combined
French and German sample of 1,138 extremely obese chil-
dren and adolescents and 1120 normal or underweight con-
trolswithscreeningof2,339,392genotypedorimputedSNPs
and testing ultimately 1,596,878 SNPs. In the replication
cohort, all SNPs with strong evidence for association were
genotyped in independent samples of 1,181 obese children
and adolescents and 1,960 normal or underweight controls
and in up to 715 nuclear families with at least one extremely
obese oﬀspring. However the two loci were, at most, only
marginally associated with adult BMI in the latest GIANT
study [98], suggesting their inﬂuence may be limited to
extreme obesity in children.
The biochemistry employed in the current genome wide
SNParraysallowsalsofortheaccurategenotypingandquan-
titation of allelic CNV genome-wide [62, 63, 65]. Neuro-
logical disorders have proven the most challenging complex
disease to address using genome wide SNP approaches, pri-
marily as a consequence of the need for strict, uniform phe-
notyping across very large, multicenter cohorts. However,
they have led the way in the uncovering of CNVs in common
disorders such as autism [107–110], attention-deﬁcit hyper-
activity disorder [111], and schizophrenia [112–114].
Genomic copy number variations (CNVs) have been
strongly implicated in subjects with extreme obesity and
coexisting developmental delay (Table 1). Two groups in
the UK plus collaborators independently reported deletions
on chromosome 16p11.2 to be present at much higher in
extreme obese cases than normal and obese individuals
[102, 103]. These deletions, estimated to range in size fromJournal of Obesity 5
Table 1: Childhood obesity loci that have been identiﬁed to date and the route through which they were implicated.
Category Loci Citations
Adult BMI GWAS loci also associated with childhood
BMI/obesity in independent studies
FTO, TMEM18, GNPDA2, INSIG2, MC4R, NEGR1, 1q25,
BDNF, KCTD15 [99]
Adult 2 type diabetes GWAS loci also associated with
childhood BMI/obesity HHEX-IDE [100]
GWAS of extreme childhood obesity—novel loci SDCCAG8, TNKS-MSRA [101]
CNV analyses of childhood obesity—novel loci SH2B1, EDIL3, S1PR5, FOXP2, TBCA, ABCB5, ZPLD1,
KIF2B, ARL15, EPHA6-UNQ6114, OR4P4-OR4S2-OR4C6 [102–105]
220kb to 1.7Mb, encompass several genes. Bochukova et al.
[102] pointed out that the SH2B1 gene is within the deleted
region that is common to all ﬁve cases studied. SH2B1 may
be the culprit as its role in leptin and insulin signaling and
energy homeostasis is well described [102], plus common
SNPs near SH2B1 locus have already been associated with
BMI in GWAS reports [96, 102].
To complement these previous CNV studies on extreme
obesity, we addressed CNVs in common childhood obesity
by examining children in the upper 5th percentile of BMI
but excluding any subject greater than 3 standard deviations
from the mean to reduce severe cases in the cohort [104]
(Table 1). We performed a whole-genome CNV survey of
our cohort of European American (EA) childhood obesity
cases (n =∼ 1,000) and lean controls (n = 2,500) who
were genotyped with 550,000 SNP markers. We identiﬁed 34
putative CNVR loci (15 deletions and 19 duplications) that
were exclusive to EA cases; however, three of the deletions
proved to be false positives during the validation process
with quantitative PCR (qPCR). Only 17 of these CNVR loci
were unique to our cohort that is, not reported in controls
by the Database of Genomic Variants. Positive ﬁndings were
evaluated in an independent African American (AA) cohort
(n =∼ 1,500) of childhood obesity cases and lean controls
(n =∼1,500). Surprisingly, eight of these loci, that is, almost
half, also replicated exclusively in AA cases (6 deletions and
2 duplications). Replicated deletion loci consisted of EDIL3,
S1PR5, FOXP2, TBCA, ABCB5, and ZPLD1 while replicated
duplication loci consisted of KIF2B and ARL15. We also
observed evidence for a deletion at the EPHA6-UNQ6114
locus when the AA cohort was investigated as a discovery set.
The majority of genes harboring at the loci uncovered
in this study have not been implicated in obesity previously.
However, the most notable ﬁnding is with ARL15, which was
recently uncovered in a GWAS of adiponectin levels, with the
same risk allele also being associated with a higher risk of
CVD and T2D [115].
We also evaluated large rare deletions present in <1%
of individuals and >500kb in size as set previously [104]
and did not observe excess of large rare deletions genome-
wide. This is not unexpected given that previous reports only
found signiﬁcance when including developmental delay sub-
jects but not when severe early-onset obesity was evaluated
alone [102, 103].
More recently, a novel common copy number variation
for early-onset extreme obesity was reported on chromo-
some 11q11, harboring the OR4P4, OR4S2,a n dOR4C6
genes using a similar approach [105]( Table 1). Indeed, as
higher and higher resolution genome wide scans are carried
out, one would expect further reports of such ﬁndings.
10.Other Ethnicities
Studying populations of diﬀerent ancestry will also help
us to globally identify and understand the genetic and
environmental factorsassociated with estimates of obesity, as
variants found in populations of both African and Caucasian
ancestry may represent more universally important genes
and pathways for subsequent diagnosis, prevention, and
treatment of obesity and its complications. In addition, a
cohort of African ancestry in many instances can aid in
reﬁning the anticipated association(s) made in with the
GWAS approach due to lower LD in this ethnicity, for
example, the association of T2D with TCF7L2 [116]h a sbee n
reﬁned utilizing a West African patient cohort [117].
To date, most obesity GWAS reports have come from
investigations of populations of European origin. This is
partly due to the relatively low haplotypic complexity of
Caucasian genomes and partly to get around admixture
concerns. Indeed, like many of the other replication eﬀorts,
FTO shows the strongest association with BMI in our large
European American pediatric cohort [98]. However, the
role of the FTO locus in inﬂuencing BMI and obesity
predisposition in populations of African ancestry has been
previously less clear [88, 118], but consensus is emerging
from large cohort studies, both in adults [119] and in our
own pediatric cohort [90], that SNP rs3751812 captures
the FTO association with the trait in both ethnicities; this
ﬁnding is comparable to similar outcomes working with loci
in asthma [120]a n dT 2 D[ 117].
11. Conclusions
While these recently discovered loci unveil several new
biomolecular pathways not previously associated with obe-
sity, it is important to note that these well-established genetic
associations with obesity explain very little of the genetic
risk for this pediatric phenotype, suggesting the existence
of additional loci whose number and eﬀect size remain
unknown.
These ﬁndings have left the genetics community to pon-
der how we are going to ﬁnally uncover the full repertoire of6 Journal of Obesity
the genetic component of given traits in order to explain the
“missing heritability” [121]. Thus, it is clear that in addition
to larger and larger cohorts combined in to meta-analyses,
new whole genome sequencing technologies will be a large
part of the solution. With new advances in sequencing, one
would expect further variants to be characterized in this
condition so collectively they could build up to a meaningful
contribution to the missing heritably for this trait.
Taken together, the unbiased genome wide approach to
assesstheentiregenomehasrevealedgenesthatunderpinthe
pathogenesisofchildhoodobesity.Furtherfunctionalstudies
will be needed to fully characterize the function of the genes
at these loci in relation to childhood obesity.
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